What Is CJC-1295 with DAC 5mg?

CJC-1295 with DAC 5mg is a long-acting derivative of GHRH designed to stimulate endogenous growth hormone release over an extended duration. Unlike shorter-acting GHRH fragments, this compound incorporates a lysine-based linker (N-epsilon-3-maleimidopropionamide) that enables reversible binding to plasma proteins, significantly extending its functional half-life in experimental models.

CJC-1295 with DAC 5mg is an experimental research compound and is not approved for human or animal use.

Research Background

CJC-1295 with DAC is based on a tetrasubstituted GHRH (1–29) sequence engineered for enhanced stability and resistance to enzymatic degradation. The addition of the DAC component differentiates it from non-DAC variants by extending the reported half-life to approximately 8 days in research models, compared to hours for standard GHRH analogs.

Despite its prolonged activity, research indicates that CJC-1295 with DAC retains strong binding affinity for GHRH receptors, supporting sustained growth hormone release in experimental settings. It has also been studied in combination research protocols, particularly alongside ghrelin receptor agonists, to explore potential synergistic signaling effects. All findings remain preclinical.

Mechanisms of Research Interest

Extended Half-Life via Drug Affinity Complex

The DAC modification allows CJC-1295 to bind reversibly to circulating plasma proteins, slowing clearance and extending biological activity in laboratory models.

GHRH Receptor Activation

CJC-1295 with DAC 5mg has been studied for its ability to bind GHRH receptors on pituitary somatotroph cells, initiating intracellular signaling pathways associated with growth hormone secretion.

Sustained Growth Hormone Signaling

Prolonged receptor engagement enables investigation into continuous or extended growth hormone signaling patterns without direct hormone administration.

Synergistic Research Applications

CJC-1295 with DAC has been examined in experimental combinations with ghrelin receptor agonists, such as Ipamorelin, to study coordinated signaling effects on growth hormone pathways.

All mechanisms described are experimental observations or theoretical models and do not imply clinical or therapeutic benefit.

Molecular and Chemical Information

• Product Name: CJC-1295 with DAC 5mg

• Form: Lyophilized powder

• Purity: Greater than 99%

• Peptide Length: 29 amino acids

• Classification: Long-acting GHRH analog

• Molecular Formula: C152H252N44O42

• Molecular Weight: 3367.95 g/mol

• Alternate Names: CJC-1295, CJC-1295 with DAC, DAC:GRF, long-acting GHRH analog, tetrasubstituted GRF (1–29) with DAC

Research Applications

CJC-1295 with DAC 5mg may be utilized by qualified researchers in laboratory investigations involving:

• Growth hormone–releasing hormone receptor signaling

• Extended-duration endocrine pathway studies

• Endogenous growth hormone and IGF-1 signaling research

• Combination protocols with ghrelin receptor agonists

All use must remain within controlled laboratory environments.

Regulatory Status and Use Disclaimer

• For research use only

• Not approved by the Food and Drug Administration

• Not intended for human or veterinary use

• Not intended to diagnose, treat, cure, or prevent any disease

• No established clinical safety, dosing, or efficacy data